Stay updated with breaking news from Early Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management.
An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.
An obesity doctor and endocrinologist weigh in.
Early onset of type 2 diabetes can reduce life expectancy by up to 14 years, highlighting the urgency for preventive measures.
A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.